GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Median PS Value

Vertex Pharmaceuticals (WBO:VRTX) Median PS Value : €526.23 (As of Dec. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €37.424. Vertex Pharmaceuticals's 10-Year median PS Ratio is 14.0613. Therefore, the Median PS Value for today is €526.23.

As of today (2024-12-14), Vertex Pharmaceuticals's share price is €440.55. Vertex Pharmaceuticals's Median PS Value is €526.23. Therefore, Vertex Pharmaceuticals's Price to Median PS Value for today is 0.84.

The historical rank and industry rank for Vertex Pharmaceuticals's Median PS Value or its related term are showing as below:

WBO:VRTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.45   Med: 0.74   Max: 2.58
Current: 0.84

During the past 13 years, the highest Price to Median PS Value of Vertex Pharmaceuticals was 2.58. The lowest was 0.45. And the median was 0.74.

WBO:VRTX's Price-to-Median-PS-Value is ranked worse than
57.2% of 264 companies
in the Biotechnology industry
Industry Median: 0.7 vs WBO:VRTX: 0.84

Vertex Pharmaceuticals Median PS Value Historical Data

The historical data trend for Vertex Pharmaceuticals's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Median PS Value Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 237.13 298.92 387.78 476.83 511.24

Vertex Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 525.55 511.24 531.36 535.50 499.35

Competitive Comparison of Vertex Pharmaceuticals's Median PS Value

For the Biotechnology subindustry, Vertex Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Price-to-Median-PS-Value falls into.



Vertex Pharmaceuticals Median PS Value Calculation

Vertex Pharmaceuticals's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=37.424*14.0613
=526.23

10-Year Median PS Ratio is 14.0613.
Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €37.424.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vertex Pharmaceuticals  (WBO:VRTX) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Vertex Pharmaceuticals's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=440.55/526.23
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vertex Pharmaceuticals Median PS Value Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.